The expression of immunohistochemical markers of human epidermal growth factor receptor 2 (HER2/neu), estrogen receptor (ER) and progesterone receptor (PR) have been widely accepted for routine use in breast cancer, serving as predictive factors of endocrine and trastuzumab therapy, respectively [10], [11]. Here, PGR is linked to breast carcinoma.